Overview

A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

Status:
Terminated
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV) infection. In addition, the study will assess antiviral efficacy of ALN-HBV in patients with HBV.
Phase:
Phase 1
Details
Lead Sponsor:
Alnylam Pharmaceuticals